Andrew J Murphy
Co-Chief Scientific Officer. Files against REGN. Everything below is filed with the SEC within two business days of the trade. Filed as MURPHY ANDREW J.
Every reported line
Purchases, sales, grants, option exercises and shares withheld for tax.
| Company | Action | Value |
|---|---|---|
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $4.5K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $26.5K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $12.1K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $18.2K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $10.6K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $56.3K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $20.6K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $41.9K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $19.1K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $167.4K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $207.4K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $213.8K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $147.3K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $80.7K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $97.7K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $9.2K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $218.4K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $163K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $173.2K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $93.7K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $291.6K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $51.2K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $29.6K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $353.5K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $296.2K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $361.4K |
| REGNRegeneron Pharmaceuticals Inc2026-10-14 | Sale10b5-1 plan | $39.1K |
| REGNRegeneron Pharmaceuticals Inc2026-10-13 | Option exercise10b5-1 plan | $6.5M |
| REGNRegeneron Pharmaceuticals Inc2026-10-13 | Withheld for tax10b5-1 plan | $9.7M |
| REGNRegeneron Pharmaceuticals Inc2026-10-13 | Option exercisederivative10b5-1 plan | — |
Sales they filed notice of
Form 144 is permission to sell, not a sale. It is routinely used in part or not at all, so these are never added to the trades above.
| Company | Shares | Value |
|---|---|---|
| REGN | 4.1K | $3.2M |
Source: SEC Form 4 and Form 144 filings, via EDGAR. Form 144 carries no filer identifier, so those notices are matched to this page by name alone. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
Follow Andrew J Murphy by email
Andrew J Murphy's new Form 4 trades, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.